pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib
Sun Yat-sen University
Sun Yat-sen University trial registry — 19 ClinicalTrials.gov studies with program phase, status, and indication context.
广州市新港西路135号, CN HQ
3,680 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 广州市新港西路135号, CN
- Employees
- 3,680
- Programs
- 19
- Drugs
- 25
- Patents
- 0
Sun Yat-sen University clinical trials
Registry index of 19 ClinicalTrials.gov studies linked to Sun Yat-sen University programs — each row shows trial ID, program name, phase, status, and indication.
Sun Yat-sen University trial registry — 19 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Sun Yat-sen University.
-
TPC induction chemotherapy — Phase 2
Clinical update -
Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine — Phase 2
Clinical update -
postoperative antimicrobial prophylaxis — Phase 3
Clinical update -
Palliative Chemotherapy — Phase 3
Clinical update -
gemcitabine and cisplatin (Induction chemotherapy) — Phase 3
Clinical update -
Cytokine-Induced Killer Cells — Phase 3
Clinical update -
Concurrent chemotherapy — Phase 1
Clinical update -
Chidamide — Phase 2
Clinical update